Does Silodosin Improve Symptoms in Benign Prostatic Hyperplasia?

Quality of life improved significantly with silodosin compared with tamsulosin in randomized crossover trial

TUESDAY, June 25, 2024 (HealthDay News) -- Silodosin improves storage and voiding symptoms in patients with benign prostatic hyperplasia (BPH), according to a study published in the January 2017 issue of the International Journal of Scientific Study.

Rathish Vishekun Rajendran, M.B.B.S., from Salem, Tanil Nadu in India, and colleagues conducted a prospective, randomized crossover drug trial involving 60 patients with BPH. Patients were randomly assigned to the silodosin preceding group (SPG) or the tamsulosin preceding group (TPG) (30 and 30, respectively). Participants received four weeks of initial treatment, followed by a one-week washout and four weeks of the crossover drug. The magnitude of symptomatology and responses to treatment were assessed using the International Prostate Symptom Score.

The researchers found that from baseline, there was a significant improvement in the maximal urinary flow rate in both groups in the first treatment period, with the SPG producing a more significant change (8.73 versus 5.93 for TPG). Quality of life (QOL) improved significantly with silodosin versus tamsulosin in the initial treatment period. A bothersome adverse drug reaction that persuaded for withdrawal of the drug did not occur in any patients.

"It is clearly evident that silodosin, a highly selective α1-A-adrenoceptor antagonist, exhibited excellent efficacy in improving subjective symptoms regardless of period of administration, and appears to improve QOL in patients with BPH/LUTS [lower urinary tract symptoms]," the authors write.

Abstract/Full Text (subscription or payment may be required)